On Tuesday, Piper Sandler adjusted its outlook on shares of Vicarious Surgical Inc. (NYSE:RBOT), lowering the company's price target to $12 from the previous $30 while maintaining a neutral stance on the stock. The revision followed the announcement of the company's second-quarter results, which showed an adjusted earnings per share (EPS) of -$2.86, narrowly missing the consensus estimate of -$2.72.
Vicarious Surgical reiterated its guidance for the full year, expecting a cash burn of approximately $50 million. Despite the shortfall in earnings expectations, the firm confirmed that it is on schedule with the development of its V1.0 system. This crucial step toward commercialization is expected to be completed by Fall 2024.
The company also provided an update on its clinical progress, indicating that it anticipates beginning surgical operations on humans around the same time next year, aligning with previous projections. This milestone is a significant part of Vicarious Surgical's path toward bringing its technology to the healthcare market.
In explaining the rationale behind the updated price target, Piper Sandler cited the company's current financial position, including its cash, cash equivalents, and short-term investments, which amount to approximately $73 million. The firm expressed continued enthusiasm for Vicarious Surgical's unique technology but chose to stick with a neutral rating until further progress and visibility towards commercialization are evident.
In other recent news, Vicarious Surgical, a robotics-driven surgical firm, reported its Q2 2024 financial results, revealing a 17% increase in operating expenses year-over-year to $17.7 million.
Despite the rise in expenses, largely due to investments in research and development (R&D) and general and administrative (SG&A) expenses, the company continues to progress with its V1.0 surgical system integration and clinical trial plans. This includes partnerships with hospital systems like LSU Health New Orleans to enhance trial activities and system validation.
The company's R&D expenses accounted for $10.9 million of the total spend, with $73 million in cash and short-term investments remaining. Vicarious Surgical is preparing for a fall launch of its V1.0 system, with final testing and subsystem evaluations underway. Despite the complexities involved, the company remains confident in its integration timeline.
While the increased operating expenses could indicate financial strain, the company's advancement in its development process and partnerships suggests potential for future growth. However, the decision to conduct clinical trials in countries like South America and Australia may suggest challenges in the U.S. regulatory environment. These are the recent developments surrounding Vicarious Surgical.
InvestingPro Insights
As Vicarious Surgical Inc. navigates its path toward commercialization, real-time data from InvestingPro offers insights into the company's financial health and stock performance. With a market capitalization of $32.34 million, the company's financials reflect significant investment in its innovative technology, yet challenges remain. The adjusted P/E ratio for the last twelve months as of Q1 2024 stands at -0.53, indicating that investors are not expecting earnings in the near term. Additionally, the stock has experienced a downturn, trading near its 52-week low and showing a price total return of -80.29% over the last year.
InvestingPro Tips highlight critical considerations for Vicarious Surgical's investors. The company holds more cash than debt, which is a positive sign for financial stability. However, it is quickly burning through cash, and analysts do not anticipate profitability this year. Moreover, the stock has suffered due to weak gross profit margins and a valuation that implies a poor free cash flow yield. For investors seeking a deeper analysis, additional InvestingPro Tips can be found at https://www.investing.com/pro/RBOT, providing a comprehensive view of the company's financial nuances.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.